Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection

Zhang, Zhanqing; Shi, Bisheng; Lu, Wei; Huang, Dan; Wang, Yanbing; Feng, Yinchang

doi:10.1016/j.jviromet.2021.114226

Cited by 12 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25,26 Therefore, the level of anti-HBc may reflect the validities of the host immune response. 27 In contrast, HBsAg was conversely correlated with inflammation grade. Previous studies showed a significant decrease in the HBsAg levels with increasing liver damage, which suggests that liver injury is mediated by the host cellular response to small epitopes of HBV proteins.…”

Section: Discussionmentioning

confidence: 98%

“…Meanwhile, viral naked HBcAg releasing from damaged hepatocytes during hepatitis and anti‐HBc as the antibody against HBcAg, which was produced by B cells, would increase with the activation of the antigen and enhanced immune function 25,26 . Therefore, the level of anti‐HBc may reflect the validities of the host immune response 27 . In contrast, HBsAg was conversely correlated with inflammation grade.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum qAnti‐HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg‐positive immune active patients

Wang

Gao

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Serum qAnti‐HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg‐positive immune active patients

Wang

Gao

et al. 2022

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…HBV DNA in patients in the early cohorts was measured by dye-based qPCR assay using a Bio-Rad Icycler PCR System (Bio-Rad Laboratories, Inc., California, USA), the reagents were purchased from Qiagen Shenzhen Co. Ltd. (Shenzhen, China), and detection range is 500 to 5 × 10 7 IU/ml ( 15 , 27 ); in patients in the late cohorts, HBV DNA was measured by probe-based qPCR assay using a Roche LightCycler 480 qPCR system (Roche, Basel, Switzerland), the reagents were purchased from Sansure Biotech Inc. (Changsha, China), and detection range is 100 to 2 × 10 9 IU/ml ( 26 , 28 ).…”

Section: Methodsmentioning

confidence: 99%

Capabilities of hepatitis B surface antigen are divergent from hepatitis B virus DNA in delimiting natural history phases of chronic hepatitis B virus infection

Zhang

Lu²,

Huang³

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

ObjectiveQuantitative hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA in the natural history of chronic HBV infection have not been rationally evaluated. This study aimed to re-characterize quantitative HBsAg and HBV DNA in the natural history phases.MethodsA total of 595 and 651 hepatitis B e antigen (HBeAg)-positive patients and 485 and 705 HBeAg-negative patients were assigned to the early and late cohorts, respectively. Based on the ‘S-shape’ receiver operating characteristic (ROC) curves, the HBeAg-positive sub-cohorts with possibly high HBV replication (PHVR) and possibly low HBV replication (PLVR) and the HBeAg-negative sub-cohorts with possibly high HBsAg expression (PHSE) and possibly low HBsAg expression (PLSE) were designated.ResultsThe areas under the ROC curve (AUCs) of HBsAg and HBV DNA in predicting HBeAg-positive significant hepatitis activity (SHA) in the early cohort, sub-cohort with PHVR, and sub-cohort with PLVR were 0.655 and 0.541, 0.720 and 0.606, and 0.553 and 0.725, respectively; those in the late cohort, sub-cohort with PHVR, and sub-cohort with PLVR were 0.646 and 0.501, 0.798 and 0.622, and 0.603 and 0.674, respectively. The AUCs of HBsAg and HBV DNA in predicting HBeAg-negative SHA in the early cohort, sub-cohort with PHSE, and sub-cohort with PLSE were 0.508 and 0.745, 0.573 and 0.780, and 0.577 and 0.729, respectively; those in the late cohort, sub-cohort with PHSE, and sub-cohort with PLSE were 0.503 and 0.761, 0.560 and 0.814, and 0.544 and 0.722, respectively. The sensitivity and specificity of HBsAg ≤4.602 log10 IU/ml in predicting HBeAg-positive SHA in the early cohort were 82.6% and 45.8%, respectively; those in the late cohort were 87.0% and 44.1%, respectively. The sensitivity and specificity of HBV DNA >3.301 log10 IU/ml in predicting HBeAg-negative SHA in the early cohort were 73.4% and 60.8%, respectively; those in the late cohort were 73.6% and 64.1%, respectively.ConclusionQuantitative HBsAg and HBV DNA are valuable, but their capabilities are divergent in delimiting the natural history phases.

show abstract

“…The phase with the lowest mean value of anti-HBc was phase 1 in all three studies, unlike a more recent study from 2021, which reported a very similar pattern of anti-HBc variations but with the lowest level in inactive phase 3 [ 29 ]. On the other hand, the latest report showed a considerably different way of anti-HBc level changes through phases of infection [ 26 ]. Mean levels constantly increased, very sharply from phases 1 to 2, then moderately from 2 to 3 and again sharply from 3 to 4, where the mean values were highest among all phases.…”

Section: Clinical Utility Of Qanti-hbcmentioning

confidence: 99%

Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas

Lazarević

Banko

Miljanovic

et al. 2023

Viruses

View full text Add to dashboard Cite

The present-day management of hepatitis B virus (HBV) infection relies on constant and appropriate monitoring of viral activity, disease progression and treatment response. Traditional HBV infection biomarkers have many limitations in predicting clinical outcomes or therapy success. Quantitation of HBV core antibodies (qAnti-HBc) is a new non-invasive biomarker that can be used in solving multiple diagnostic problems. It was shown to correlate well with infection phases, level of hepatic inflammation and fibrosis, exacerbations during chronic infection and presence of occult infection. Further, the level of qAnti-HBc was recognised as predictive of spontaneous or therapy-induced HBeAg and HBsAg seroclearance, relapse after therapy discontinuation, re-infection after liver transplantation and viral reactivation upon immunosuppression. However, qAnti-HBc cannot be relied upon as a single diagnostic test to solve all dilemmas, and its diagnostic and prognostic power can be much improved when combined with other diagnostic biomarkers (HBV DNA, HBeAg, qHBsAg and anti-HBs antibodies). The availability of commercial qAnti-HBc diagnostic kits still needs to be improved. The comparison of results from different studies and definitions of universal cut-off values continue to be hindered because many methods are only semi-quantitative. The clinical utility of qAnti-HBc and the methods used for its measurement are the focus of this review.

show abstract

Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection

Cited by 12 publications

References 35 publications

Serum qAnti‐HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg‐positive immune active patients

Serum qAnti‐HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg‐positive immune active patients

Capabilities of hepatitis B surface antigen are divergent from hepatitis B virus DNA in delimiting natural history phases of chronic hepatitis B virus infection

Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas

Contact Info

Product

Resources

About